27/01/2017
PXP Research
In-Vitro Study done at the University of Stevens Point Wisconsin
Preliminary research performed at the University of Wisconsin – Stevens Point has shown that the polysaccharide-peptide complexes in Alfa PXP have the ability to increase Cellular ATP as quantified through ATP Dependent Oxidation of Luciferin by Luciferase. Continued research may also suggest an improvement in the ADP to ATP kinetics.
In-Vivo Study on Patients with Various Diseases
A randomized illness study was done to obtain and evaluate the effects of Alfa PXP on patients with various diseases/conditions like diabetes (type I and type II), hypertension, stroke, multiple sclerosis, uterine fibroid tumor (myoma), goiter, asthma, myasthenia gravis, breast cancer, Parkinson’s disease, nephrotic syndrome, end-stage renal failure and old age. The patients include males and females with age ranging from 10 to 92 years old.
A dialectologist, pulmonologist, patholologist, chemist, physical therapist, registered nurse, and respiratory therapist supervised the research, conducted over three (3) months. Patients were given Alfa PXP with a dosage of one scoop (5 mg) three times a day before meals. Each serving was dissolved in 100-150 ml of water, either cold or hot.
The findings of the study are as follows:
Diabetic patients
Ninety (90) percent of the patients decreased their dosage of insulin injection.
Seventy-five (75) percent decreased their oral medication intake.
Eighty (80) percent experienced weight reduction.
Seventy (75) percent reduced their blood pressure.
Ninety (90) percent had reduced numbness.
Ninety (90) percent had improvement of vision.
Ninety (90) percent of the patients felt increased energy and stamina.
Ninety (90) percent regained back their libido (sexual function).
In a separate study, seventeen members of the Diabetic Association of Pateros, Philippines, participate in a study to assess the outcome/benefits of taking PXP for 90 days (three months). The clinical study that was supervised by a dialectologist was conducted from June 2006 to September 2006.
The study showed that all the patients saw a decline in their HbA1c. The most notable change was in one patients’ HbA1c which saw a change of 52.6 percent, a reduction from 9.5 to 4.5.
Stroke patients
Ninety (90) percent had increased muscle strength on the upper and lower limbs; each patient gained a 50 to 60 percent muscle strength increase.
Seventy-five (75) percent of the patients decreased muscle tightness on their shoulder and elbow, which resulted in increased range of motion axis from 45 to 180 degrees.
Of the nephrotic syndrome and end- stage renal failure patients that are on dialysis, 66 percent had decreased their dialysis sessions to once a week from twice a week while the rest, 34percent, had been out of dialysis.
Ninety (90) percent of the patients no longer need blood transfusions and weekly Eprex injections.
All patients can now urinate and sweat regularly.
There was a 90 percent reduction of edema on face and proximal extremities (both upper and lower).
Laboratory report shows a 50-60 percent decrease in creatinine and BUN levels.
The electrolytes had normalized by 90 percent specifically phosphorus, calcium, potassium.
Multiple sclerotic patients
Multiple sclerotic patients with paralysis are now able to walk and mobility function with up to 80 percent improvement. There has been a reduction of involuntary eye muscle movement by 60 percent.
Myoma patients
Frequent sharp pain on their abdomen diminished by 90 percent.
The size of tumor or mass found in their uterine was reduced by 90 percent. The smaller ones diminished totally.
Goiter patients
Reduced their mass size by 60 percent.
Ninety (90 percent) of patients eliminated their palpitations.
Breathing and swallowing improved by 70 percent.
Asthmatic patients
Asthmatics attacks lessened by 90 percent. The use of bronchodilators and steroids (inhaler/MDI) was reduced by 90 percent.
Breast cancer
The need for chemotherapy was ruled out by 90 percent.
Radiating pain from the breast to back diminished totally. Swelling and tenderness of breast lessened by 90 percent.
Parkinson’s disease
Patients experienced less tremors or trembling in hands, arms, legs, jaw, and face. The rigidity or stiffness of limbs and trunk also lessened.
Myasthenia Gravis
Increased energy and stamina enabled patient to do daily activities.
Increased immune system against infections, fever, cough and colds which can trigger upper body muscle weakness.
Medication of one tablet (Mestinon) for the muscles was reduced by half daily (from taking them every 8 hours instead of every 4 hours).
Elderly (old age)
Ninety (90) percent had increased energy/stamina level.
Symptoms of frequent body pains, constipation and difficulty in sleeping reduced.
Overall, the use of Alfa PXP for 3 months, with dosage of 3 scoops a day, showed a significant improvement on the above listed conditions.
* The information contained in this website is information only and is not intended to diagnose, treat or cure any disease. For medical advice please contact your personal health care provider.PXP Research
In-Vitro Study done at the University of Stevens Point Wisconsin
Preliminary research performed at the University of Wisconsin – Stevens Point has shown that the polysaccharide-peptide complexes in Alfa PXP have the ability to increase Cellular ATP as quantified through ATP Dependent Oxidation of Luciferin by Luciferase. Continued research may also suggest an improvement in the ADP to ATP kinetics.
In-Vivo Study on Patients with Various Diseases
A randomized illness study was done to obtain and evaluate the effects of Alfa PXP on patients with various diseases/conditions like diabetes (type I and type II), hypertension, stroke, multiple sclerosis, uterine fibroid tumor (myoma), goiter, asthma, myasthenia gravis, breast cancer, Parkinson’s disease, nephrotic syndrome, end-stage renal failure and old age. The patients include males and females with age ranging from 10 to 92 years old.
A dialectologist, pulmonologist, patholologist, chemist, physical therapist, registered nurse, and respiratory therapist supervised the research, conducted over three (3) months. Patients were given Alfa PXP with a dosage of one scoop (5 mg) three times a day before meals. Each serving was dissolved in 100-150 ml of water, either cold or hot.
The findings of the study are as follows:
Diabetic patients
Ninety (90) percent of the patients decreased their dosage of insulin injection.
Seventy-five (75) percent decreased their oral medication intake.
Eighty (80) percent experienced weight reduction.
Seventy (75) percent reduced their blood pressure.
Ninety (90) percent had reduced numbness.
Ninety (90) percent had improvement of vision.
Ninety (90) percent of the patients felt increased energy and stamina.
Ninety (90) percent regained back their libido (sexual function).
In a separate study, seventeen members of the Diabetic Association of Pateros, Philippines, participate in a study to assess the outcome/benefits of taking PXP for 90 days (three months). The clinical study that was supervised by a dialectologist was conducted from June 2006 to September 2006.
The study showed that all the patients saw a decline in their HbA1c. The most notable change was in one patients’ HbA1c which saw a change of 52.6 percent, a reduction from 9.5 to 4.5.
Stroke patients
Ninety (90) percent had increased muscle strength on the upper and lower limbs; each patient gained a 50 to 60 percent muscle strength increase.
Seventy-five (75) percent of the patients decreased muscle tightness on their shoulder and elbow, which resulted in increased range of motion axis from 45 to 180 degrees.
Of the nephrotic syndrome and end- stage renal failure patients that are on dialysis, 66 percent had decreased their dialysis sessions to once a week from twice a week while the rest, 34percent, had been out of dialysis.
Ninety (90) percent of the patients no longer need blood transfusions and weekly Eprex injections.
All patients can now urinate and sweat regularly.
There was a 90 percent reduction of edema on face and proximal extremities (both upper and lower).
Laboratory report shows a 50-60 percent decrease in creatinine and BUN levels.
The electrolytes had normalized by 90 percent specifically phosphorus, calcium, potassium.
Multiple sclerotic patients
Multiple sclerotic patients with paralysis are now able to walk and mobility function with up to 80 percent improvement. There has been a reduction of involuntary eye muscle movement by 60 percent.
Myoma patients
Frequent sharp pain on their abdomen diminished by 90 percent.
The size of tumor or mass found in their uterine was reduced by 90 percent. The smaller ones diminished totally.
Goiter patients
Reduced their mass size by 60 percent.
Ninety (90 percent) of patients eliminated their palpitations.
Breathing and swallowing improved by 70 percent.
Asthmatic patients
Asthmatics attacks lessened by 90 percent. The use of bronchodilators and steroids (inhaler/MDI) was reduced by 90 percent.
Breast cancer
The need for chemotherapy was ruled out by 90 percent.
Radiating pain from the breast to back diminished totally. Swelling and tenderness of breast lessened by 90 percent.
Parkinson’s disease
Patients experienced less tremors or trembling in hands, arms, legs, jaw, and face. The rigidity or stiffness of limbs and trunk also lessened.
Myasthenia Gravis
Increased energy and stamina enabled patient to do daily activities.
Increased immune system against infections, fever, cough and colds which can trigger upper body muscle weakness.
Medication of one tablet (Mestinon) for the muscles was reduced by half daily (from taking them every 8 hours instead of every 4 hours).
Elderly (old age)
Ninety (90) percent had increased energy/stamina level.
Symptoms of frequent body pains, constipation and difficulty in sleeping reduced.
Overall, the use of Alfa PXP for 3 months, with dosage of 3 scoops a day, showed a significant improvement on the above listed conditions.
* The information contained in this website is information only and is not intended to diagnose, treat or cure any disease. For medical advice please contact your personal health care provider.
